Stefano Palma1, Timothy Hasenoehrl1, Galateja Jordakieva1, Dariga Ramazanova2, Richard Crevenna3. 1. Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. 2. Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Medical University of Vienna, Vienna, Austria. 3. Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. richard.crevenna@meduniwien.ac.at.
Abstract
PURPOSE: To evaluate the impact of high-intensity interval training (HIIT) on health-related outcome parameters in the prehabilitation of patients diagnosed with cancer. METHODS: A systematic review and meta-analysis of comparative studies on HIIT in cancer prehabilitation conducted by screening standard databases from their inception to March 30, 2020. Outcomes of interest included cardiorespiratory fitness, feasibility, safety, clinical, and patient-reported outcomes. RESULTS: Of the 855 identified studies, 8 articles met the inclusion criteria (7 randomized, 1 non-randomized controlled trial) with a total of 896 patients. The study protocols were heterogeneous, but the methodological quality ranged from good to high according to PEDro scale. Meta-analysis revealed a significant improvement of peak oxygen consumption (VO2peak) achieved with HIIT compared to usual care. Furthermore, HIIT was feasible and safe, showing low risk of adverse events and positive effects on health-related outcomes in prehabilitative settings. CONCLUSION: In the phase of prehabilitation, HIIT has potential health benefits in patients diagnosed with cancer and is feasible and safe to perform. Nonetheless, larger randomized controlled trials focusing on long-term effects (such as cancer recurrence or survival rates) are missing, to underline the potential relevance of HIIT for cancer patients.
PURPOSE: To evaluate the impact of high-intensity interval training (HIIT) on health-related outcome parameters in the prehabilitation of patients diagnosed with cancer. METHODS: A systematic review and meta-analysis of comparative studies on HIIT in cancer prehabilitation conducted by screening standard databases from their inception to March 30, 2020. Outcomes of interest included cardiorespiratory fitness, feasibility, safety, clinical, and patient-reported outcomes. RESULTS: Of the 855 identified studies, 8 articles met the inclusion criteria (7 randomized, 1 non-randomized controlled trial) with a total of 896 patients. The study protocols were heterogeneous, but the methodological quality ranged from good to high according to PEDro scale. Meta-analysis revealed a significant improvement of peak oxygen consumption (VO2peak) achieved with HIIT compared to usual care. Furthermore, HIIT was feasible and safe, showing low risk of adverse events and positive effects on health-related outcomes in prehabilitative settings. CONCLUSION: In the phase of prehabilitation, HIIT has potential health benefits in patients diagnosed with cancer and is feasible and safe to perform. Nonetheless, larger randomized controlled trials focusing on long-term effects (such as cancer recurrence or survival rates) are missing, to underline the potential relevance of HIIT for cancerpatients.
Authors: Gregg Nelson; Jamie Bakkum-Gamez; Eleftheria Kalogera; Gretchen Glaser; Alon Altman; Larissa A Meyer; Jolyn S Taylor; Maria Iniesta; Javier Lasala; Gabriel Mena; Michael Scott; Chelsia Gillis; Kevin Elias; Lena Wijk; Jeffrey Huang; Jonas Nygren; Olle Ljungqvist; Pedro T Ramirez; Sean C Dowdy Journal: Int J Gynecol Cancer Date: 2019-03-15 Impact factor: 3.437
Authors: Ulrik Wisløff; Tom I L Nilsen; Wenche B Drøyvold; Siv Mørkved; Stig A Slørdahl; Lars J Vatten Journal: Eur J Cardiovasc Prev Rehabil Date: 2006-10
Authors: M Keilani; T Hasenoehrl; L Baumann; R Ristl; M Schwarz; M Marhold; T Sedghi Komandj; R Crevenna Journal: Support Care Cancer Date: 2017-06-10 Impact factor: 3.603
Authors: Sara Mijwel; Anna Jervaeus; Kate A Bolam; Jessica Norrbom; Jonas Bergh; Helene Rundqvist; Yvonne Wengström Journal: J Cancer Surviv Date: 2019-03-25 Impact factor: 4.442
Authors: Steven C Moore; I-Min Lee; Elisabete Weiderpass; Peter T Campbell; Joshua N Sampson; Cari M Kitahara; Sarah K Keadle; Hannah Arem; Amy Berrington de Gonzalez; Patricia Hartge; Hans-Olov Adami; Cindy K Blair; Kristin B Borch; Eric Boyd; David P Check; Agnès Fournier; Neal D Freedman; Marc Gunter; Mattias Johannson; Kay-Tee Khaw; Martha S Linet; Nicola Orsini; Yikyung Park; Elio Riboli; Kim Robien; Catherine Schairer; Howard Sesso; Michael Spriggs; Roy Van Dusen; Alicja Wolk; Charles E Matthews; Alpa V Patel Journal: JAMA Intern Med Date: 2016-06-01 Impact factor: 21.873
Authors: Hans-Olov Adami; Anton Berns; Julio E Celis; Elisabeth de Vries; Alexander Eggermont; Adrian Harris; Harald Zur Hausen; Pier Giuseppe Pelicci; Ulrik Ringborg Journal: Mol Oncol Date: 2018-09-21 Impact factor: 6.603
Authors: Jaidyn Muhandiramge; John R Zalcberg; G J van Londen; Erica T Warner; Prudence R Carr; Andrew Haydon; Suzanne G Orchard Journal: Curr Oncol Rep Date: 2022-07-07 Impact factor: 5.075
Authors: Marta K Mikkelsen; Cecilia M Lund; Anders Vinther; Anders Tolver; Julia S Johansen; Inna Chen; Anne-Mette Ragle; Bo Zerahn; Lotte Engell-Noerregaard; Finn O Larsen; Susann Theile; Dorte L Nielsen; Mary Jarden Journal: Oncologist Date: 2022-02-03 Impact factor: 5.837
Authors: Jaidyn Muhandiramge; Suzanne G Orchard; Erica T Warner; Gijsberta J van Londen; John R Zalcberg Journal: Cancers (Basel) Date: 2022-03-08 Impact factor: 6.639